WO1996040073A3 - Composition for sustained release of non-aggregated erythropoietin - Google Patents
Composition for sustained release of non-aggregated erythropoietin Download PDFInfo
- Publication number
- WO1996040073A3 WO1996040073A3 PCT/US1996/008474 US9608474W WO9640073A3 WO 1996040073 A3 WO1996040073 A3 WO 1996040073A3 US 9608474 W US9608474 W US 9608474W WO 9640073 A3 WO9640073 A3 WO 9640073A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- sustained release
- biologically active
- epo
- polymer
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1658—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5052—Proteins, e.g. albumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ309533A NZ309533A (en) | 1995-06-07 | 1996-06-03 | Composition for sustained release of non-aggregated erythropoietin |
AU59724/96A AU705451B2 (en) | 1995-06-07 | 1996-06-03 | Composition for sustained release of non-aggregated erythropoietin |
JP9501068A JPH11506764A (en) | 1995-06-07 | 1996-06-03 | Non-aggregated erythropoietin sustained release composition |
EP96917028A EP0871433A2 (en) | 1995-06-07 | 1996-06-03 | Composition for sustained release of non-aggregated erythropoietin |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/478,502 US5716644A (en) | 1992-06-11 | 1995-06-07 | Composition for sustained release of non-aggregated erythropoietin |
US08/478,502 | 1995-06-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1996040073A2 WO1996040073A2 (en) | 1996-12-19 |
WO1996040073A3 true WO1996040073A3 (en) | 1997-01-23 |
Family
ID=23900212
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/008474 WO1996040073A2 (en) | 1995-06-07 | 1996-06-03 | Composition for sustained release of non-aggregated erythropoietin |
Country Status (11)
Country | Link |
---|---|
US (1) | US5716644A (en) |
EP (1) | EP0871433A2 (en) |
JP (1) | JPH11506764A (en) |
CN (1) | CN1177612C (en) |
AU (1) | AU705451B2 (en) |
CA (1) | CA2223834A1 (en) |
CZ (1) | CZ390897A3 (en) |
MX (1) | MX9709699A (en) |
NZ (1) | NZ309533A (en) |
PL (1) | PL323736A1 (en) |
WO (1) | WO1996040073A2 (en) |
Families Citing this family (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030035845A1 (en) * | 1992-06-11 | 2003-02-20 | Zale Stephen E. | Composition for sustained release of non-aggregated erythropoietin |
US5981719A (en) | 1993-03-09 | 1999-11-09 | Epic Therapeutics, Inc. | Macromolecular microparticles and methods of production and use |
US6090925A (en) | 1993-03-09 | 2000-07-18 | Epic Therapeutics, Inc. | Macromolecular microparticles and methods of production and use |
AUPO066096A0 (en) * | 1996-06-26 | 1996-07-18 | Peptide Delivery Systems Pty Ltd | Oral delivery of peptides |
US20020052309A1 (en) * | 1996-09-11 | 2002-05-02 | Athanasius A. Anagnostou | Method of treating endothelial injury |
DE69705746T2 (en) | 1996-12-20 | 2001-10-31 | Alza Corp | INJECTABLE DEPOT GEL PREPARATION AND PRODUCTION METHOD |
US6531154B1 (en) | 1997-06-10 | 2003-03-11 | Brown University Research Foundation | Modulated release from biocompatible polymers |
US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
US20030180368A1 (en) * | 1998-03-14 | 2003-09-25 | Cenes Drug Delivery Limited | Production of microparticles |
AR020848A1 (en) * | 1998-10-23 | 2002-05-29 | Amgen Inc | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF ANEMIA |
US7304150B1 (en) * | 1998-10-23 | 2007-12-04 | Amgen Inc. | Methods and compositions for the prevention and treatment of anemia |
US6444223B1 (en) | 1999-05-28 | 2002-09-03 | Alkermes Controlled Therapeutics, Inc. | Method of producing submicron particles of a labile agent and use thereof |
US20030211974A1 (en) * | 2000-03-21 | 2003-11-13 | Brodbeck Kevin J. | Gel composition and methods |
AU2005225151B2 (en) * | 2000-05-15 | 2008-05-29 | F. Hoffmann-La Roche Ag | New pharmaceutical composition |
WO2001087329A1 (en) * | 2000-05-15 | 2001-11-22 | F. Hoffmann-La Roche Ag | Liquid pharmaceutical composition containing an erythropoietin derivate |
US20020076443A1 (en) * | 2000-06-19 | 2002-06-20 | Stanley Stein | Multiple phase cross-linked compositions and uses thereof |
US6998393B2 (en) * | 2000-06-23 | 2006-02-14 | Biopharm Solutions, Inc. | Aquespheres, their preparation and uses thereof |
US6719970B1 (en) | 2000-07-10 | 2004-04-13 | Alkermes Controlled Therapeutics, Inc. | Method of generating cartilage |
US6296842B1 (en) | 2000-08-10 | 2001-10-02 | Alkermes Controlled Therapeutics, Inc. | Process for the preparation of polymer-based sustained release compositions |
US6479065B2 (en) | 2000-08-10 | 2002-11-12 | Alkermes Controlled Therapeutics, Inc. | Process for the preparation of polymer-based sustained release compositions |
WO2002013786A2 (en) * | 2000-08-15 | 2002-02-21 | Board Of Trustees Of The University Of Illinois | Method of forming microparticles |
US6824822B2 (en) * | 2001-08-31 | 2004-11-30 | Alkermes Controlled Therapeutics Inc. Ii | Residual solvent extraction method and microparticles produced thereby |
US6558702B2 (en) * | 2001-04-13 | 2003-05-06 | Alkermes Controlled Therapeutics, Inc. | Method of modifying the release profile of sustained release compositions |
US20060269602A1 (en) * | 2001-04-13 | 2006-11-30 | Dasch James R | Method of modifying the release profile of sustained release compositions |
AU2002320122B2 (en) | 2001-06-21 | 2007-07-26 | Genentech, Inc. | Sustained release formulation |
US6818613B2 (en) * | 2001-11-07 | 2004-11-16 | Ortho-Mcneil Pharmaceutical, Inc. | Aqueous sustained-release formulations of proteins |
EP2491943B1 (en) | 2003-02-04 | 2018-10-10 | Cornell Research Foundation, Inc. | Methods for preventing mitochondrial permeability transition |
CA2524258C (en) | 2003-05-01 | 2012-08-07 | Cornell Research Foundation, Inc. | Carrier complexes comprising cationic peptides for delivering molecules to cells |
EP1677735B1 (en) | 2003-10-17 | 2014-07-23 | Joslin Diabetes Center, Inc. | Methods and compositions for modulating adipocyte function |
US7309500B2 (en) * | 2003-12-04 | 2007-12-18 | The Board Of Trustees Of The University Of Illinois | Microparticles |
WO2005063965A1 (en) * | 2003-12-30 | 2005-07-14 | Bionethos Holding Gmbh | Tissue regeneration method |
JP4931604B2 (en) | 2004-01-23 | 2012-05-16 | コーネル リサーチ ファウンデイション インコーポレイテッド | Methods for reducing oxidative damage |
CN1980974A (en) * | 2004-04-23 | 2007-06-13 | 安姆根有限公司 | Low molecular weight polymers |
US20050260272A1 (en) * | 2004-05-05 | 2005-11-24 | Alkermes Controlled Therapeutics, Inc. | Method of forming microparticles that include a bisphosphonate and a polymer |
AU2005325213B2 (en) * | 2004-08-04 | 2010-10-07 | Evonik Corporation | Methods for manufacturing delivery devices and devices thereof |
US7772182B2 (en) * | 2004-08-05 | 2010-08-10 | Alza Corporation | Stable suspension formulations of erythropoietin receptor agonists |
US20060029551A1 (en) * | 2004-08-05 | 2006-02-09 | Kui Liu | Stable particle formulations of erythropoietin receptor agonists |
US7748343B2 (en) | 2004-11-22 | 2010-07-06 | The Board Of Trustees Of The University Of Illinois | Electrohydrodynamic spraying system |
CA2621786A1 (en) * | 2005-08-29 | 2007-03-08 | Tuo Jin | Polysaccharide microparticles containing biological agents: there preparation and applications |
CA2947335A1 (en) | 2005-09-16 | 2007-03-29 | Cornell Research Foundation, Inc. | Methods for reducing cd36 expression |
ES2718612T3 (en) | 2007-12-20 | 2019-07-03 | Evonik Corp | Procedure for preparing microparticles that have a low volume of residual solvent |
CA2713150C (en) | 2008-02-07 | 2016-01-05 | Cornell University | Methods for preventing or treating insulin resistance |
CN106975070A (en) | 2008-02-26 | 2017-07-25 | 康奈尔大学 | Method for preventing and treating acute injury of kidney |
EP2283119B1 (en) | 2008-05-06 | 2015-01-07 | Joslin Diabetes Center, Inc. | Methods and compositions for inducing brown adipogenesis |
CA2749993C (en) * | 2009-01-23 | 2016-12-20 | Surmodics Pharmaceuticals, Inc. | Continuous double emulsion process for making microparticles |
CN103933542A (en) | 2009-03-20 | 2014-07-23 | 通用医疗公司以马萨诸塞州通用医疗公司名义经营 | Methods For The Prevention And Treatment Of Burn Injuries And Secondary Complications |
JP2010251707A (en) * | 2009-03-27 | 2010-11-04 | Fujitsu Ltd | Wiring board, and semiconductor device |
JP5909182B2 (en) * | 2009-08-12 | 2016-04-26 | コーネル ユニヴァーシティー | Methods for preventing or treating metabolic syndrome |
EP3318264A1 (en) | 2009-08-24 | 2018-05-09 | Stealth Peptides International, Inc. | Methods ans compositions for preventing or treating opthalmic conditions |
BR112012006443A2 (en) * | 2009-09-22 | 2017-07-25 | Evonik Degussa Corp | implant devices that feature variable loading configurations of bioactive agents |
EP2944317A1 (en) * | 2009-10-05 | 2015-11-18 | Cornell University | Methods for the prevention or treatment of heart failure |
EP3090754A1 (en) | 2009-12-31 | 2016-11-09 | Stealth Peptides International, Inc. | Methods for the prevention or treatment of vessel occlusion injury |
US20130190244A1 (en) | 2009-12-31 | 2013-07-25 | Stealth Peptides International, Inc. | Methods for performing a coronary artery bypass graft procedure |
CA2787331A1 (en) | 2010-01-25 | 2011-07-28 | Hazel H. Szeto | Aromatic-cationic peptides and uses of same |
EP2538958A4 (en) | 2010-02-26 | 2013-08-28 | Univ Florida | Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy |
EP3560508A1 (en) | 2010-03-15 | 2019-10-30 | Stealth Peptides International, Inc. | Combination therapies using cyclosporine and aromatic cationic peptides |
EP3450447A1 (en) | 2010-05-03 | 2019-03-06 | Stealth Peptides International, Inc. | Aromatic-cationic peptides and uses of same |
CA2804404C (en) | 2010-07-09 | 2020-10-20 | Stealth Peptides International, Inc. | Methods for the prevention or treatment of no-reflow following ischemia/reperfusion injury |
WO2012050673A1 (en) | 2010-10-14 | 2012-04-19 | Wisconsin Alumni Research Foundation | Methods for the treatment of x-linked hypophosphatemia and related disorders |
EP3488941A1 (en) | 2011-03-24 | 2019-05-29 | Cornell University | Aromatic-cationic peptides and uses of same |
JP6157481B2 (en) | 2011-09-29 | 2017-07-05 | メイヨ ファンデーション フォア メディカル エディケイション アンド リサーチ | Aromatic cationic peptides and methods of use thereof |
AU2012326496B2 (en) | 2011-10-17 | 2017-08-24 | Cornell University | Aromatic-cationic peptides and uses of same |
EP2788013A4 (en) | 2011-12-09 | 2015-08-19 | Stealth Peptides Int Inc | Aromatic-cationic peptides and uses of same |
EP3078384A1 (en) | 2012-02-22 | 2016-10-12 | Stealth Peptides International, Inc. | Methods and compositions for preventing or treating ophthalmic conditions |
EP2817021B1 (en) | 2012-02-23 | 2019-01-02 | Cornell University | Aromatic-cationic peptides and uses of same |
CA2880648A1 (en) | 2012-08-02 | 2014-02-06 | Stealth Peptides International, Inc. | Methods for treatment of atherosclerosis |
EP3586862B1 (en) | 2012-10-22 | 2021-12-08 | Stealth Peptides International, Inc. | Methods for reducing risks associated with heart failure and factors associated therewith |
JP2016506391A (en) | 2012-12-06 | 2016-03-03 | ステルス ペプチドズ インターナショナル インコーポレイテッド | Peptide therapeutic agent and method of use thereof |
HUE046924T2 (en) | 2013-03-01 | 2020-03-30 | Stealth Biotherapeutics Corp | Methods and compositions for the prevention or treatment of barth syndrome |
CN105517533A (en) | 2013-03-01 | 2016-04-20 | 康德生物医疗技术公司 | Methods for the treatment of mitochondrial disease |
JP2016522196A (en) | 2013-05-14 | 2016-07-28 | ステルス バイオセラピューティックス コープ | Methods for prevention or treatment of left ventricular remodeling |
WO2014210062A1 (en) | 2013-06-26 | 2014-12-31 | Stealth Peptides International, Inc. | Methods for the regulation of matrix metalloproteinase expression |
US9877997B2 (en) | 2013-06-26 | 2018-01-30 | Stealth Biotherapeutics Corp | Methods and compositions for regulating SRCA2A expression levels in myocardial infarction |
CA2916977A1 (en) | 2013-06-26 | 2014-12-31 | Stealth Biotherapeutics Corp | Methods and compositions for detecting and diagnosing diseases and conditions |
WO2014210056A1 (en) | 2013-06-27 | 2014-12-31 | Stealth Peptides International, Inc. | Peptide therapeutics and methods for using same |
US20160166633A1 (en) | 2013-08-02 | 2016-06-16 | Stealth Bio Therapeutics Corp | Methods and compositions for the prevention and treatment of friedreich's ataxia |
JP2016540762A (en) | 2013-12-02 | 2016-12-28 | ステルス バイオセラピューティックス コープ | Compositions and methods for the treatment of vitiligo |
EP3502132A1 (en) | 2014-05-28 | 2019-06-26 | Stealth BioTherapeutics Corp | Therapeutic compositions including therapeutic small molecules and uses thereof |
CA2950428C (en) | 2014-05-28 | 2022-11-29 | Stealth Biotherapeutics Corp | Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof |
EP3151827A4 (en) | 2014-06-04 | 2018-01-24 | Tersus Pharmaceuticals, LLC | METHODS OF TREATING CHRONIC DRY EYE DISEASE USING C16:1n7 PALMITOLEATE AND DERIVATIVES THEREOF |
CA2952615A1 (en) | 2014-06-17 | 2015-12-23 | Stealth Biotherapeutics Corp | Methods of identifying and monitoring mitochondrial dysfunction using monocyte screening |
CA2958585C (en) | 2014-08-21 | 2024-01-09 | Stealth Biotherapeutics Corp | Use of peptide d-arg-2',6'-dmt-lys-phe-nh2 for the treatment of alport syndrome |
WO2017059338A1 (en) | 2015-10-02 | 2017-04-06 | Cornell University | Enzyme-responsive peptide nanofiber compositions and uses thereof |
CN116196389A (en) | 2016-01-06 | 2023-06-02 | 康德生物医疗有限公司 | Methods and compositions for preventing and treating duchenne muscular dystrophy |
CN117205298A (en) | 2016-05-19 | 2023-12-12 | 康德生物医疗有限公司 | Compositions and methods for preventing and treating mitochondrial myopathy |
CN106273027A (en) * | 2016-08-19 | 2017-01-04 | 安庆仁生塑胶有限公司 | A kind of uniformly plastic particle blender |
CA3072200A1 (en) | 2017-08-08 | 2019-02-14 | Memorial Sloan Kettering Cancer Center | Use of braf inhibitors for treating cutaneous reactions caused by treatment with a mek inhibitor |
RU2705723C1 (en) * | 2018-06-26 | 2019-11-11 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Южно-Уральский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО ЮУГМУ Минздрава России) | Rectal suppositories with erythropoietin, having reparative and antioxidant activity |
AU2019392670A1 (en) | 2018-12-06 | 2021-07-01 | Stealth Biotherapeutics Inc. | Methods and compositions for the treatment of Sengers syndrome |
EP3976646A4 (en) | 2019-05-28 | 2023-04-19 | Shanghaitech University | Composition and methods to treat ectodermal dysplasia 2, clouston type |
AU2020316449A1 (en) | 2019-07-24 | 2022-02-10 | Stealth Biotherapeutics Inc. | The peptidomimetic compound (R)-2-amino-N-((S)-L-(((S)-5-amino-L-(3-benzyl-1,2,4-oxadiazol-5-yl)pentyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-l-oxopropan-2-yl)-5-guanidinopentanamide in the treatment of neurodegenerative diseases |
US11584728B2 (en) | 2019-10-04 | 2023-02-21 | Stealth Biotherapeutics Inc. | Compositions and methods for the prevention and/or treatment of mitochondrial disease, including Friedreich's ataxia |
KR20230005855A (en) | 2020-04-03 | 2023-01-10 | 스텔스 바이오테라퓨틱스 인코포레이티드 | Compositions and methods for preventing and/or treating mitochondrial diseases, including Friedreich's ataxia |
WO2023069255A1 (en) | 2021-10-20 | 2023-04-27 | Stealth Biotherapeutics Inc. | Methods and compositions comprising peptidomimitics for treating, preventing, inhibiting, ameliorating or delaying the onset of ophthalmic conditions |
WO2023101963A2 (en) | 2021-11-30 | 2023-06-08 | Northwestern University | Compositions for inhibiting dipeptide repeat protein-ribosomal rna interaction and uses thereof |
WO2023133321A1 (en) | 2022-01-10 | 2023-07-13 | Stealth Biotherapeutics Inc. | Small molecule peptidomimetic for the treatment of tauopathies |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993025221A1 (en) * | 1992-06-11 | 1993-12-23 | Alkermes Controlled Therapeutics, Inc. | Erythropoietin drug delivery system |
WO1996007399A1 (en) * | 1994-09-09 | 1996-03-14 | Takeda Chemical Industries, Ltd. | Sustained release preparation containing metal salt of a peptide |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3699244A (en) * | 1971-08-23 | 1972-10-17 | Singer Co | Apparatus to match the color of a monochrome display to average color of an adjacent full color display |
US4675189A (en) * | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
IE52535B1 (en) * | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US4637905A (en) * | 1982-03-04 | 1987-01-20 | Batelle Development Corporation | Process of preparing microcapsules of lactides or lactide copolymers with glycolides and/or ε-caprolactones |
US4906474A (en) * | 1983-03-22 | 1990-03-06 | Massachusetts Institute Of Technology | Bioerodible polyanhydrides for controlled drug delivery |
JPS60100516A (en) * | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | Preparation of sustained release microcapsule |
US4891225A (en) * | 1984-05-21 | 1990-01-02 | Massachusetts Institute Of Technology | Bioerodible polyanhydrides for controlled drug delivery |
JPS6191131A (en) * | 1984-10-09 | 1986-05-09 | Chugai Pharmaceut Co Ltd | Method and composition for preventing adsorption of pharmaceutical |
JPS6197229A (en) * | 1984-10-18 | 1986-05-15 | Chugai Pharmaceut Co Ltd | Stable erythropoietin preparation |
US4732889A (en) * | 1985-02-06 | 1988-03-22 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition for the treatment of the anemia of rheumatoid arthritis |
US4962091A (en) * | 1986-05-23 | 1990-10-09 | Syntex (U.S.A.) Inc. | Controlled release of macromolecular polypeptides |
US4981696A (en) * | 1986-12-22 | 1991-01-01 | E. I. Du Pont De Nemours And Company | Polylactide compositions |
JPS6427374A (en) * | 1987-03-19 | 1989-01-30 | Eizou Center Kk | Large screen display device |
DE3729863A1 (en) * | 1987-09-05 | 1989-03-16 | Boehringer Mannheim Gmbh | STABILIZED ERYTHROPOIETIN LYOPHILISATES |
US4897268A (en) * | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
GB2209937B (en) * | 1987-09-21 | 1991-07-03 | Depiopharm S A | Water insoluble polypeptides |
JP2708189B2 (en) * | 1988-09-16 | 1998-02-04 | 日本放送協会 | Wide field of view stereoscopic image display method and apparatus |
US4990336A (en) * | 1989-02-08 | 1991-02-05 | Biosearch, Inc. | Sustained release dosage form |
US5019400A (en) * | 1989-05-01 | 1991-05-28 | Enzytech, Inc. | Very low temperature casting of controlled release microspheres |
US5126147A (en) * | 1990-02-08 | 1992-06-30 | Biosearch, Inc. | Sustained release dosage form |
FR2658432B1 (en) * | 1990-02-22 | 1994-07-01 | Medgenix Group Sa | MICROSPHERES FOR THE CONTROLLED RELEASE OF WATER-SOLUBLE SUBSTANCES AND PREPARATION METHOD. |
JPH0463092A (en) * | 1990-06-29 | 1992-02-28 | Sanyo Electric Co Ltd | Three-dimensional scene display system |
WO1992011844A1 (en) * | 1991-01-03 | 1992-07-23 | Alkermes Controlled Therapeutics, Inc. | Stabilization of proteins by cationic biopolymers |
AU2605592A (en) * | 1991-10-15 | 1993-04-22 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
US5288502A (en) * | 1991-10-16 | 1994-02-22 | The University Of Texas System | Preparation and uses of multi-phase microspheres |
DE69311538D1 (en) * | 1992-03-12 | 1997-07-17 | Alkermes Inc | ACTH CONTAINED MICROBALLS WITH CONTROLLED DISCHARGE |
DK0674506T3 (en) * | 1992-12-02 | 2001-01-08 | Alkermes Inc | Controlled release growth hormone-containing microspheres |
-
1995
- 1995-06-07 US US08/478,502 patent/US5716644A/en not_active Expired - Fee Related
-
1996
- 1996-06-03 AU AU59724/96A patent/AU705451B2/en not_active Ceased
- 1996-06-03 CZ CZ973908A patent/CZ390897A3/en unknown
- 1996-06-03 NZ NZ309533A patent/NZ309533A/en unknown
- 1996-06-03 CA CA002223834A patent/CA2223834A1/en not_active Abandoned
- 1996-06-03 PL PL96323736A patent/PL323736A1/en unknown
- 1996-06-03 JP JP9501068A patent/JPH11506764A/en not_active Ceased
- 1996-06-03 EP EP96917028A patent/EP0871433A2/en not_active Withdrawn
- 1996-06-03 WO PCT/US1996/008474 patent/WO1996040073A2/en not_active Application Discontinuation
- 1996-06-03 CN CNB961946113A patent/CN1177612C/en not_active Expired - Fee Related
-
1997
- 1997-12-05 MX MX9709699A patent/MX9709699A/en not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993025221A1 (en) * | 1992-06-11 | 1993-12-23 | Alkermes Controlled Therapeutics, Inc. | Erythropoietin drug delivery system |
WO1996007399A1 (en) * | 1994-09-09 | 1996-03-14 | Takeda Chemical Industries, Ltd. | Sustained release preparation containing metal salt of a peptide |
Also Published As
Publication number | Publication date |
---|---|
AU705451B2 (en) | 1999-05-20 |
MX9709699A (en) | 1998-07-31 |
CN1187134A (en) | 1998-07-08 |
US5716644A (en) | 1998-02-10 |
EP0871433A2 (en) | 1998-10-21 |
AU5972496A (en) | 1996-12-30 |
PL323736A1 (en) | 1998-04-14 |
CA2223834A1 (en) | 1996-12-19 |
CN1177612C (en) | 2004-12-01 |
CZ390897A3 (en) | 1998-05-13 |
WO1996040073A2 (en) | 1996-12-19 |
JPH11506764A (en) | 1999-06-15 |
NZ309533A (en) | 1999-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1996040073A3 (en) | Composition for sustained release of non-aggregated erythropoietin | |
WO1996040072A3 (en) | Composition for sustained release of human growth hormone | |
CA2226166A1 (en) | Biocompatible and biodegradable nanoparticles designed for proteinaceous drugs absorption and delivery | |
HU910707D0 (en) | Preparation of regulated emission of active substance and process for manufacturing it | |
AU658715B2 (en) | A process for the preparation of biologically active material-containing polymeric microcapsules | |
EP0761212A3 (en) | Effervescent composition and its production | |
CA2224074A1 (en) | System and method for producing drug-loaded microparticles | |
NZ508470A (en) | Matrices formed of polymer and hydrophobic compounds for use in sustained release drug delivery | |
CA2033277A1 (en) | Controlled release pharmaceutical preparation and method for producing the same | |
HUT54861A (en) | Process for producing dosage units, dosage units in pressed form and their application | |
CA2303432A1 (en) | Modulation of drug loading in multivesicular liposomes | |
AU5962496A (en) | Improved formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents | |
HUT50050A (en) | Pharmaceutical compositions with controlled release of active ingredient and process for producing such compositions | |
CA2304662A1 (en) | Methods for fabricating polymer-based controlled release preparations | |
DE69532673D1 (en) | MICROCAPSULES FOR THE ADMINISTRATION OF NEUROACTIVE ACTIVE SUBSTANCES | |
CA2136434A1 (en) | Erythropoietin drug delivery system | |
DE69735688T2 (en) | Controlled release microparticles | |
AU5673399A (en) | Compositions and methods for treating intracellular infections | |
PL317996A1 (en) | Carbamazepinic form of a drug with retarded release of biologically active substance | |
CA2384301A1 (en) | Sustained-release drug formulations for implantation | |
CA2189254A1 (en) | Modulated release from biocompatible polymers | |
Chang | DUAL POLYMER MICROSPHERE SYSTEMS TO CONTROL DRUG RELEASE (CHLORPROMAZINE, POLYESTERS, CELLULOSE DERIVATIVES) | |
WO2000076484A1 (en) | Pharmaceutical preparation with delayed release of an active substance |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 96194611.3 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 309533 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 1997 501068 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2223834 Country of ref document: CA Ref document number: 2223834 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV1997-3908 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996917028 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: PV1997-3908 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1996917028 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: PV1997-3908 Country of ref document: CZ |